Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,154,197 papers from all fields of science
Search
Sign In
Create Free Account
cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine
Known as:
Rituximab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine
, R-CHOP Regimen
, Rituxan/CHOP
Expand
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and mantle cell lymphoma and is being studied in the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Cyclophosphamide
Doxorubicin
Doxorubicin Hydrochloride
Lymphoma, Non-Hodgkin
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Aktuelle Therapiestrategien beim diffusen großzelligen B‑Zell-Lymphom
M. Pfreundschuh
Der Internist
2016
Corpus ID: 13520067
ZusammenfassungDas diffuse großzellige B‑Zell-Lymphom („diffuse large B‑cell lymphoma“ –DLBCL) ist das häufigste Non-Hodgkin…
Expand
2016
2016
外科手术及利妥昔单抗对原发胃弥漫大B细胞淋巴瘤患者生存的影响
海雯 Haiwen 黄 Huang
,
亦彬 Yibin 蒋 Jiang
,
+4 authors
德. D. 吴 Wu
Zhonghua xue ye xue za zhi = Zhonghua xueyexue…
2016
Corpus ID: 6348828
目的 探讨手术联合化疗与单纯化疗对原发胃弥漫大B细胞淋巴瘤(PGDLBCL)患者生存的影响,并分析化疗过程中联合应用利妥昔单抗(R)对其预后的影响。 方法 回顾性分析83例PGDLBCL患者的临床资料,并分析外科手术及利妥昔单抗对患者生存的影响。 结果 83…
Expand
2015
2015
MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma
Haibo Huang
,
Jun-jiao Gu
,
+7 authors
Yanyan Liu
2015
Corpus ID: 72168517
Aim: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure is a…
Expand
2008
2008
Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient.
A. Lokare
,
S. Chaganti
,
G. Lipkin
,
C. Roberts
,
P. Mahendra
Transplantation
2008
Corpus ID: 2387323
Posttransplant lymphoproliferative disorder (PTLD) is an uncommon but potentially fatal complication affecting 1% to 3% of renal…
Expand
2008
2008
Severe skin necrosis after rituximab-CHOP therapy.
I. Botden
,
M. Leys
,
A. V. van Houten
,
R. Peeters
Netherlands Journal of Medicine
2008
Corpus ID: 12726138
2006
2006
Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
L. Elbl
,
I. Vášová
,
+4 authors
Jiří Vorlíček
Neoplasma (Bratislava)
2006
Corpus ID: 25900841
Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and…
Expand
2006
2006
Serum levels and pharmacokinetic of rituximab in Bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial:
M. Reiser
,
M. Wenger
,
C. Nickenig
,
N. Peter
,
B. Metzner
,
M. Pfreundschuh
2006
Corpus ID: 221199329
7537 Background: The combination of Rituximab (R) and CHOP is considered the standard of treatment for DLBCL in elderly patients…
Expand
1994
1994
Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen
L. Trümper
,
C. Renner
,
+4 authors
M. Pfreundschuh
1994
Corpus ID: 56954054
Background: The efficacy of chemotherapy protocols for the treatment of high-grade non-Hodgkin’s lymphoma (NHL) has not improved…
Expand
1989
1989
[Peripheral T-cell lymphoma initially presenting as secondary myelofibrosis].
K. Takai
,
M. Sanada
[Rinsho ketsueki] The Japanese journal of…
1989
Corpus ID: 24304824
A case of peripheral T-cell lymphoma presenting with secondary myelofibrosis and meningeal involvement is described. A 65-year…
Expand
Review
1978
Review
1978
Adriamycin and other anthracycline antibiotics under study in the United States.
R. Benjamin
Recent results in cancer research. Fortschritte…
1978
Corpus ID: 22810529
Adriamycin is now firmly established as a drug with a very broad spectrum of antitumor activity. It has had a major impact on the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE